Current overview and treatment of mantle cell lymphoma

about

Current overview and treatment of mantle cell lymphoma

Item

http://www.wikidata.org/entity/Q57174710

description

scientific article published on 25 July 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Current overview and treatment of mantle cell lymphoma

@en

Current overview and treatment of mantle cell lymphoma

@nl

type

Item

label

Current overview and treatment of mantle cell lymphoma

@en

Current overview and treatment of mantle cell lymphoma

@nl

prefLabel

Current overview and treatment of mantle cell lymphoma

@en

Current overview and treatment of mantle cell lymphoma

@nl

P1476

Current overview and treatment of mantle cell lymphoma

@en

P2093

Leo I Gordon

http://www.w3.org/2001/XMLSchema#string

P2860

Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

P304

1136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12688/F1000RESEARCH.14122.1

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Reem Karmali

Michael Schieber

P577

2018-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30109020

http://www.w3.org/2001/XMLSchema#string

P932

6069726

http://www.w3.org/2001/XMLSchema#string